Clinical Trial

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 16, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-30; most recent amendment 2025-07-13.
Status change: Not Yet Recruiting → Recruiting 2025-07-13
Trial Details
NCT Number NCT06962865
Lead Sponsor RemeGen Co., Ltd.
Conditions Non-Small Cell Lung Cancer
Enrollment 80 participants
Start Date 2025-06-30
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-16